Zusammenfassung
Nur bei etwa 60% der Patienten kommen in den Blutbildern — und dann meist wenige — „hairy cells“ vor. Sie zeichnen sich durch die namensgebenden langen Ausläufer des meist weiten und unruhig gefärbten Zytoplasmas aus. Zusammen mit dem eher lockeren und oft weit gebuchteten Kern sind Hairy cells meist ohne weiteres zuzuordnen. Nukleolen sind nur sehr diskret erkennbar. Anisozytose, Monozytopenie und niedrige Retikulozytenzahlen stützen die Vermutung einer Haarzell-Leukämie (HZL).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Damasio E, Carella AM (ICGHCL) (1995) Treatment of HCL with 2-chlorodeoxyadenosine (2-CDA) in two different schedules. Blood (suppl):3230
Dearden CE, Matutes E, Hilditch BL et al (1999) Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine Br J Haematol 106:515–519
Flinn IW, Kopecky KJ, Foucar MK et al (2000) Long-term follow-up of remissions duration, mortality, and second malignancies in hairy cell leukaemia patients with pentostatin. Blood 96:2981–2986
Hagberg H, Lundholm L (2001) Rituximab, a clinical anti-CD20 monoclonal antibody in the treatment of hairy cell leukemia. Br J Haematol 115:609–611
Hakimian D, Tallman MS, Kiley C, Peterson L (1993) Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 82:1798–1802
Hoffmann MA, Janson D, Rose E et al (1997) Treatment of hairy cell leukemia with cladribine: response, toxicity and long-term follow-up. J Clin Oncol 15:1138–1142
Kreitman RJ, Wilson WH, Bergeron K et al (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Eng J Med 345:241–247
Meyer U, Strehl J, Gorschlüter M et al (2003) Advances in the treatment of hairy cell leukemia. Lancet Oncol 4:86–94
Nielsen B, Braide I (1992) Three years continuous low-dose interferon-alpha treatment of hairy-cell leukemia: Evaluation of response and maintenance dose. Eur J Haematol 49:174–179
Saven A, Piro LD: Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2′-deoxycoformycin. Ann Intern Med 119:278–283
Seymour JF, Talpaz M, Kurzrock R (1995) Splenectomized patients have more rapid recovery of CD4+ lymphocytes following deoxycoformycin: Long-term follow-up of patients with hairy cell leukemia resistant to interferon. Blood (suppl):1391
Smith II JW, Longo DL, Urba WJ et al (1991) Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-α 2a. Blood 78:1664–1671
Thaler J, Grunewald K, Gattringer C et al (1993) Long-term follow-up of patients with hairy cell leukemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration. Br J Haematol 84:75–82
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Pralle, H., Schmidt-Wolf, I. (2006). Haarzell-Leukämie. In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-31303-6_174
Download citation
DOI: https://doi.org/10.1007/3-540-31303-6_174
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-20657-6
Online ISBN: 978-3-540-31303-8
eBook Packages: Medicine (German Language)